Navigation Links
Lilly Comments on 2011 Financial Guidance and Announces 2012 Financial Guidance
Date:1/5/2012

tivity and the company's current dividend.

Webcast of Conference Call

As previously announced, investors, media and the general public can access a live webcast of the 2012 financial guidance conference call through a link on Lilly's website at www.investor.lilly.com. The conference call will be held today beginning at 9:30 a.m. Eastern Standard Time (EST) and will be available for replay via the website through March 2, 2012.

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers – through medicines and information – for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com; Lilly's clinical trial registry is available at www.lillytrials.com.

F-LLY

This press release contains forward-looking statements that are based on management's current expectations, but actual results may differ materially due to various factors. There are significant risks and uncertainties in pharmaceutical research and development. There can be no guarantees with respect to pipeline products that the products will receive the necessary clinical and manufacturing regulatory approvals or that they will prove to be commercially successful. Pharmaceutical products can develop unexpected safety or efficacy concerns. The company's results may also be affected by such factors as competitive developments affecting current products, including the impact of generic competition; market uptake of recently-launched products; the timing of anticipated regulatory approvals and launches of new products; regulatory actions regarding currently marketed
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
3. Lilly and Glenmark Pharmaceuticals Announce License Agreement
4. Lilly Receives NCQA Design Certification for Depression Care Management Program
5. JDRF and Lilly Partner to Fund Research to Identify Beta Cell Biomarkers
6. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
7. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
8. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
9. Lilly Launches Its First Phase III Trial for Treatment of Alzheimers Disease
10. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
11. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... LOS ANGELES , May 24, 2013  An ... gathered on Saturday, May 18, in Santa ... findings on new lung-sparing therapies for MPM, a rare ... and commonly affects the pleura, the lining of the ... Heart, Lung and Blood Institute, the 3rd Annual International ...
(Date:5/24/2013)... May 24, 2013 In accordance with Rule 17.1 ... 14e-1 of the United States Exchange Act, Echo Pharma Acquisition ... for Elan Corporation (NYSE: ELN). Background ... made an offer for the entire of the issued and ... (the "Original Offer").  On 20 May 2013, ...
(Date:5/23/2013)... 24, 2013 3SBio Inc. (NASDAQ: ... leading China -based biotechnology company ... products, announced today that, at an extraordinary general ... voted in favor of the proposal to authorize ... of merger dated February 8, 2013, among Decade ...
Breaking Medicine Technology:International Mesothelioma Experts Present Promising New Research Findings at the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma 2International Mesothelioma Experts Present Promising New Research Findings at the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma 3Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 2Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 3Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 4Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 5Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 6Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 7Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 8Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 93SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 23SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 3
... 16, 2011 Cancer patients in China ... the announcement that a leading cancer center is acquiring ... VAR). This device is the first high dose rate ... leader in radiotherapy systems. Jilin University ...
... 16, 2011 U L ... announced today that it has filed an abbreviated 510(k) application ... label claim to include the management and mitigation of pain. ... a randomized clinical study comparing Altrazeal® to Acquacel® Ag in ...
Cached Medicine Technology:First Varian High Dose Rate Brachytherapy Afterloader Supplied to Leading China Cancer Hospital 2ULURU Inc. Announces the Filing of a 510(k) Application to Expand Altrazeal®'s Label Claim 2ULURU Inc. Announces the Filing of a 510(k) Application to Expand Altrazeal®'s Label Claim 3ULURU Inc. Announces the Filing of a 510(k) Application to Expand Altrazeal®'s Label Claim 4
(Date:5/24/2013)... NY (PRWEB) May 24, 2013 ... (AICASA) has signed an articulation agreement with ... students to study abroad in Antigua. , ... college credits after participating in a cell biology course, ... articulation agreement with American University of Antigua (AUA) ...
(Date:5/24/2013)... (PRWEB) May 24, 2013 The ... of products used outside the central laboratory, by ... a healthcare practitioner or by consumers. This includes ... fertility and pregnancy, infectious and cardiovascular disease and ... such as critical care, surgical and emergency departments. ...
(Date:5/24/2013)... than half of recommended well-child visits had up to ... attended most of their visits, according to a study ... Care . The study included more than 20,000 children ... chronic conditions like asthma and heart disease were even ... according to the study. In fact, children with ...
(Date:5/24/2013)... is available in German . ... "alpha-synuclein" aggregates and accumulates within neurons. Specific areas of ... and advances. The mechanism underlying this pathological progression is ... protein (or abnormal forms of it) along nerve projections ... the German Center for Neurodegenerative Diseases (DZNE) in Bonn ...
(Date:5/24/2013)... presented today shows that formation of new neurons in ... importance in learning and remembering - could cause forgetting ... brain circuits. Drs. Paul Frankland and Sheena Josselyn, ... argue this reorganization could have the positive effect of ... for new learning. These results were presented at ...
Breaking Medicine News(10 mins):Health News:AICASA Signs Articulation Agreement with Old Dominion University to Create Study Abroad Program 2Health News:Point of Care Diagnostics Market (POC) Analysis and 5 Year Forecast in New Research Report at ReportsnReports.com 2Health News:Point of Care Diagnostics Market (POC) Analysis and 5 Year Forecast in New Research Report at ReportsnReports.com 3Health News:Young children who miss well-child visits are more likely to be hospitalized 2Health News:Young children who miss well-child visits are more likely to be hospitalized 3Health News:Proteins in migration 2Health News:Proteins in migration 3Health News:Proteins in migration 4Health News:New neuron formation could increase capacity for new learning, at the expense of old memories 2
... woman who dines with a man, chances are you choose food ... is one of the findings in a study conducted by researchers ... of the international journal Appetite . Meredith Young, PhD ... what a person chooses to eat at lunch or dinner is ...
... N.J., Aug. 5 Most people over the age of 40 ... on nearby objects. Although this age related phenomena is usually assisted ... in Tokyo, Japan and published in March, 2009 has shown significant ... subjects (mean age of 53.9 +/- 5.1 years) with supplementation of ...
... , FORT LAUDERDALE, Fla., Aug. 5 In ... Boston and Miami, discussions are now focusing on how massive recoveries ... health reform initiatives. This latest sweep was the third in two ... has recovered more than $370 million. , , ...
... WASHINGTON, Aug. 5 The National Council on Disability (NCD) ... people with disabilities at 9:45 a.m. on August 12 at ... Conference on Community Preparedness -- The Power ... Hotel, 2799 Jefferson Davis Highway, Arlington, VA. NCD Vice Chairperson ...
... ... combine industry-leading RFID software, services with industry-first RFID laser printing capabilities to create ... ... 5, 2009 -- Today, FileTrail Inc, the leading provider of browser-based records management software ...
... , , Goal to ... Agencies Should Empanel Scientific Advisory Committees Solely of Members ... , WASHINGTON, Aug. 5 A bipartisan panel ... on the White House and federal agencies to make specific ...
Cached Medicine News:Health News:What you eat depends on with whom you eat 2Health News:The Reduction of Eye Fatigue Improves Vision in Older Subjects 2Health News:Multi-state Medicare Fraud Crackdown Focuses Attention on Recovery Payoffs to Defray Health Reform Costs 2Health News:FileTrail Joins With Lexmark To Offer End-to-End RFID-Enabled Item Management, Tracking, and Printing Solutions 2Health News:FileTrail Joins With Lexmark To Offer End-to-End RFID-Enabled Item Management, Tracking, and Printing Solutions 3Health News:FileTrail Joins With Lexmark To Offer End-to-End RFID-Enabled Item Management, Tracking, and Printing Solutions 4Health News:Bipartisan Panel of Industry, NGO and Academic Experts Proposes New Rules for Science in Federal Regulation 2Health News:Bipartisan Panel of Industry, NGO and Academic Experts Proposes New Rules for Science in Federal Regulation 3Health News:Bipartisan Panel of Industry, NGO and Academic Experts Proposes New Rules for Science in Federal Regulation 4Health News:Bipartisan Panel of Industry, NGO and Academic Experts Proposes New Rules for Science in Federal Regulation 5Health News:Bipartisan Panel of Industry, NGO and Academic Experts Proposes New Rules for Science in Federal Regulation 6
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
VascoScrew is a unipolar permanent pacing lead with a fixed screw a double flanch for permanent pacing. Due to latest technologies, VascoScrew D10/60 M is compatible to all pacemaker-cavities with th...
VascoTwist is a low profile unipolar permanent pacing lead with a retractable screw. Due to advanced technology VascoTwist 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm...
VascoScrew is a low profile unipolar pacing lead with a fixed screw for permanent pacing. Due to latest technologies, VascoScrew 6/60 M is compatible to all pacemaker-cavities with the size of IS-1 (...
Medicine Products: